BRCA1 Protein Deficiency in Breast Cancer Microbiopsy Lysate Delineates Patient Survival Time

Sara Hounguè¹, Terence Totah², Sophia George³, Jean-Léon Olory-Togbé⁴ and Callinice D. Capo-chichi^1,

¹University of Abomey Calavi (UAC), Faculty of Sciences and Technics (FAST), Department of Biochemistry and Cell Biology; laboratory of Molecular Biomarkers in Cancer and Nutrition (BMCN)

²University of Abomey Calavi (UAC), Faculty of Health Sciences, Department of Public Health, Laboratory of Chronic and Neural Diseases Epidemiology (LEMACEN)

³University of Abomey Calavi (UAC), Faculty of Health Sciences, Department of Visceral Surgery and Oncology, National University Hospital Center-HKM (CNHU-HKM)

⁴University of Miami (UM), Miller School of Medicine, Department of obstetrics and gynecology, Division of Oncology, Sylvester Comprehensive Cancer Center (SCCC), Miami, FL, USA

Cite this paper:
Sara Hounguè, Terence Totah, Sophia George, Jean-Léon Olory-Togbé and Callinice D. Capo-chichi. BRCA1 Protein Deficiency in Breast Cancer Microbiopsy Lysate Delineates Patient Survival Time. Journal of Cancer Research and Treatment. 2021; 9(1):1-11. doi: 10.12691/jcrt-9-1-1

Abstract

Introduction: Breast-Cancer gene 1(BRCA1) encodes for protein which has many cellular functions including DNA damage repair and maintenance of genome integrity. Malfunction or deficiency of BRCA1 protein, due to mutations or epigenetic inactivation, may provoke breast epithelial cell dedifferentiation and initiate cancer. In fact, mutants of BRCA1 predispose to breast and ovarian cancers. In the past this biomarker was not investigated for breast cancer prevention and care in Benin. The aim of our work is to assess the expression pattern of BRCA1 gene and protein in precancerous and cancerous breast tissue microbiopsies to determine the molecular mechanisms underlying BRCA1 protein suppression and potentiate prognosis and targeted personalized therapy in Benin. Method: This study obtains the institutional ethical approval. Microbiopsy tissues (n = 54) were collected in the Visceral surgery department of the National University Hospital Center HKM (CNHU-HKM) located in the city of Cotonou (Benin) for diagnosis and prognosis purposes. Polymerase chain reaction (PCR) technic with primers targeting Exon 1 and Exon 2 of BRCA1 was used to assess gene transcription capability. Immunoblotting was used to determine BRCA1 protein profile in breast cancer tissue microbiopsy lysates. Ethical approval was obtained for this study. Kaplan–Meier curves analysis was performed to determine the median survival time according to BRCA1 gene and protein patterns. Results: We observed that 87% of samples had lost the expression of BRCA1 protein. Among them, 78% of the loss was not associated to gene deletion. The disparity between the presence of the BRCA1 gene and the lack of protein expression suggested that the silencing of BRCA1 may be due to epigenetic inactivation in most patients. Ultimately, Kaplan Meyer’s survival curve analysis showed that the lack of BRCA1 amplification at Exon 1 or Exon 2 diminished the median survival time of cancer patients to 20 months. Conclusion: BRCA1 protein translation is impaired by Exon 1 or Exon 2 mutation /deletion along with epigenetic inactivation in breast cancer; all together influences median survival time. The delineation of the molecular mechanism underlying BRCA1 gene inactivation leading to protein deficiency will be an excellent molecular tool for African breast cancer prognostic and personalized targeted therapy in the future.

Keywords:
breast cancer microbiopsy BRCA1 silencing median survival time prognosis

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Valencia OM, Samuel SE, Viscusi RK, Riall TS, Neumayer LA, Aziz H. The Role of Genetic Testing in Patients with Breast Cancer: A Review. JAMA Surg., 2017; 152:589-94.
[2]	Adeloye D, Sowunmi OY, Jacobs W, David RA, Adeosun AA, Amuta AO, et al.. Estimating the incidence of breast cancer in Africa: a systematic review and meta-analysis. J Glob Health 2018, 8:010419.
[3]	IACR/WHO. Cancer today (2019). International Agency for Cancer Research and WHO. http://gco.iarc.fr/today/home.
[4]	DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Breast cancer statistics, CA Cancer J Clin, 2019; 69:438-51.
[5]	CDC. United States Cancer Statistics: Data Visualizations. Leading Cancer Cases and Deaths, Black, Female, 2017. https://gis.cdc.gov/Cancer/USCS/DataViz.html.
[6]	Akarolo-Anthony SN, Ogundiran TO, Adebamowo CA. Emerging breast cancer epidemic: evidence from Africa. Breast Cancer Res, 2010; 12 Suppl 4:S8.
[7]	Corbex M., Bouzbid S., Boffetta P. Features of breast cancer in developing countries, examples from North-Africa. Eur J Cancer, 2014; 50:1808-18.
[8]	Foerster M, Anderson BO, McKenzie F, Galukande M, Anele A, Adisa C. et al. Inequities in breast cancer treatment in sub-Saharan Africa: findings from a prospective multi-country observational study. Breast Cancer Res, 2019; 21(1): 93.
[9]	Capo-chichi CD, Alladagbin DJ, Brun L, Aguida B, Agossou KV, Anagbla T, et al. Deficiency of GATA6 as a Molecular Tool to Assess the Risk for Cervical Cancer. American Journal of Biomedical Research, 2014; 2: 1-6.
[10]	Egue M, Gnangnon FHR, Akele-Akpo MT, Maxwell Parkin D. Cancer incidence in Cotonou (Benin), 2014-2016: First results from the cancer Registry of Cotonou. Cancer Epidemiol, 2019; 59: 46-50.
[11]	Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science, 1990; 250: 1684-9.
[12]	Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet, 1992; 2: 128-31.
[13]	Economopoulou P., Dimitriadis G., Psyrri A. Beyond BRCA: new hereditary breast cancer susceptibility genes. Cancer Treat Rev, 2015; 41: 1-8.
[14]	Downs B. and Wang SM. Epigenetic changes in BRCA1-mutated familial breast cancer. Cancer Genet, 2015; 208: 237-240.
[15]	Sharma B, Preet Kaur R, Raut S, Munshi A. BRCA1 mutation spectrum, functions, and therapeutic strategies: The story so far. Curr Probl Cancer, 2018; 42: 189-207.
[16]	Levy-Lahad E., Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer, 2007; 96(1):11-5.
[17]	George SH, Shaw P. BRCA and Early Events in the Development of Serous Ovarian Cancer. Front Oncol, 2014; 4:5.
[18]	Sawyer S.L., Tian L., Kähkönen M., Schwartzentruber J., Kircher M., Majewski J., et al. Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype. Cancer Discov, 2015; 5:135-42.
[19]	Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 1994; 266:66-71.
[20]	Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, King MC. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet, 1994; 8:399-404.
[21]	Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci, 2004; 95:866-71.
[22]	Chalabi N, Le Corre L, Maurizis JC, Bignon YJ, Bernard-Gallon DJ. The effects of lycopene on the proliferation of human breast cells and BRCA1 and BRCA2 gene expression. European Journal of Cancer, 2004; 40: 1768-75.
[23]	Romagnolo APG, Romagnolo DF, Selmin OI. BRCA1 as target for breast cancer prevention and therapy. Anticancer Agents Med Chem, 2015; 15: 4-14.
[24]	Abul-Husn NS, Soper ER, Odgis JA, Cullina S, Bobo D, Moscati A, Rodriguez JE. CBIPM Genomics Team. Regeneron Genetics Center, Loos RJF, Cho JH, Belbin GM, Suckiel SA, Kenny EE. Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank. Genome Med, 2019; 12: 2.
[25]	Lee E.H., Park S.K., Park B., Kim S.W., Lee M.H., Ahn S.H., Son B.H., Yoo K.Y., Kang D., KOHBRA Research Group; Korean Breast Cancer Society. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: A systematic review and meta-analysis. Breast Cancer Res Treat, 2010; 122: 11-25.
[26]	Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res, 2010; 12: R12.
[27]	Vocka M, Zimovjanova M, Bielcikova Z, Tesarova P, Petruzelka L, Mateju M,et al. Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers. Cancers. 2019; 11: 738.
[28]	Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer, 2007; 109: 1721-8.
[29]	Bethea T.N., Rosenberg L., Castro-Webb N., Lunetta K..L, Sucheston-Campbell L.E., Ruiz-Narváez E.A., et al. Family history of cancer in relation to breast cancer subtypes in African American women. Cancer Epidemiol Biomarkers Prev, 2016; 25: 366-73.
[30]	Wu L., Wang F., Xu R., Zhang S., Peng X., Feng Y., Wang J., Lu C. Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis. Breast Cancer Res Treat, 2013; 142: 619-627.
[31]	Lara K, Nigmet N, Pérez J, Porco A. BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela. Biol Res, 2012; 45: 117-30.
[32]	Venkitaraman AR. How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility? DNA Repair (Amst)., 2019; 81: 102668.
[33]	Capo-chichi CD, Aguida B, Chabi NW, Cai QK, Offrin G, Agossou VK, et al. Lamin A/C deficiency is an independent risk factor for cervical cancer. Cell Oncol (Dordr), 2016; 39: 59-68.
[34]	Capo-chichi CD, Aguida B, Chabi NW, Acapko-Ezin J, Sossah-Hiffo J, Agossou VK, et al. Diversity of high-risk human papilloma viruses in women treated with antiretroviral and in healthy controls and discordance with cervical dysplasia in the South of Benin. Infect Agents Cancer, 2016; 11: 43.
[35]	Capo-chichi CD, Gnangnon F, Mekpossi C, Houngue S, Xu XX, Olory-Togbé JL. Presence of Lamin A is Required for GATA3 and ERα Downregulation by Histone Deacetylase Inhibitor in Breast Cancer Cells. Journal of Cancer Research and Treatment, 2018; 6: 60-9.
[36]	Huszno J, Kołosza Z, Grzybowska E. BRCA1 mutation in breast cancer patients: Analysis of prognostic factors and survival. Oncol Lett, 2019; 17: 1986-1995.
[37]	Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res, 2006; 8: R38.
[38]	Huo S., Ikpatt F., Khramtsov A., Dangou J.M., Nanda R., Dignam J. et al. Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer. J Clin Oncol, 2009; 27: 4515-21.
[39]	Kwan ML, Weltzien E, Kushi LH, Castillo A, Slattery ML, Caan BJ. Dietary Patterns and Breast Cancer Recurrence and Survival Among Women with Early-Stage Breast Cancer. J Clin Oncol, 2009; 27: 919-926.
[40]	Dean M, Boland J, Yeager M, Im KM, Garland L. et al. Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2. GigaScience, 2015; 4:50.
[41]	Ye Q, Hu YF, Zhong H, Anne C. Nye AC, Belmont AS, Li R. BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations. J Cell Biol,2001; 155:911-921.
[42]	Houngue S, Aguida B, Capo-chichi CD. Dynamism of Ribosomal Protein RPL28 as Biomarker for Monitoring Epigenetic-initiated-breast-cancer Therapy. American Journal of Biomedical Research, 2019; 7, 21-26.
[43]	Chatterjee B, Ghosh K, Kanade SR. Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21 CIP1 in human breast cancer cell lines. Biofactors, 2019; 45: 818-829.